GlassScriptPhysician profile
Meredith Hutchens
NPI 1235791906
$2,425.42
in general payments reported to CMS, 2019-2025
38 companies · $970 in 2025
The $970 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $388 · 2024: $1,068 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.48 |
| Education | $169.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $389.97 | 2023-2025 | Opdivo, Reblozyl |
| Astellas Pharma US INC | $261.10 | 2024-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $206.71 | 2023-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $137.13 | 2023-2025 | Tagrisso |
| Incyte Corporation | $100.85 | 2023-2025 | Jakafi |
| Array Biopharma INC | $99.88 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Janssen Biotech, INC. | $98.95 | 2024-2025 | Darzalex, Rybrevant, Imbruvica |
| Genentech USA, INC. | $89.46 | 2024-2025 | Tecentriq, Venclexta |
| Celgene Corporation | $70.73 | 2024-2025 | Reblozyl |
| Seagen INC. | $67.79 | 2023 | Tukysa, Adcetris, Tivdak |
| Caris Mpi, INC. | $63.42 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $56.43 | 2024-2025 | Injectafer, Enhertu |
| Eisai INC. | $54.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.71 | 2024-2025 | Ninlaro, Alunbrig |
| Ipsen Biopharmaceuticals, INC | $48.67 | 2025 | Onivyde |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Hutchens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.